Why the study?
ACTION was established as a learning health care system to unite stakeholders to improve outcomes for pediatric and congenital heart disease patients with heart failure.
This review highlights how the ACTION multicenter learning health network has leveraged real-world data and quality improvement collaborations to reduce pediatric VAD stroke rates, harmonize heart failure medical therapies, and secure FDA pediatric labeling for advanced cardiac devices.
Answers are grounded in this paper and cite their sources.
May guide pediatric HF device selection via registries; leaves open prospective outcome validation.
The Advanced Cardiac Therapies Improving Outcomes Network (ACTION) was founded in 2017 as a learning health care system to bring together all stakeholders with the aim of improving outcomes for pediatric and congenital heart disease patients with heart failure. From an initial focus on the ventricular assist device (VAD) population, work in the network has expanded to encompass the scope of heart failure in these patients. Through the collection and use of real-world data, the field has gained greater understanding of best practices in care of these patients, as well as improved access to devices with pediatric labeling of devices previously approved only for adults. Recent and current work across the network's major focus areas (VAD, heart failure, muscular dystrophy, and Fontan) are highlighted.
No takes yet. Share an insight, caveat, or question.
Wright et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: